The Role of Aryl Hydrocarbon Receptor in Musculoskeletal Frailty with HIV Treatment
Author Information
Author(s): Tripathi Alok, Sultana Shabiha, Shi Huidong, MacArthur Rodger, de Chantemele Eric Belin, Hamrick Mark, Lawrence Meghan McGee
Primary Institution: Augusta University
Hypothesis
Can the aryl hydrocarbon receptor (AhR) mediate musculoskeletal frailty in patients on anti-retroviral therapy (ART) for HIV?
Conclusion
The study suggests that targeting AhR may improve musculoskeletal function in patients with HIV on ART.
Supporting Evidence
- FTC increased AhR transcriptional activity and expression in myoblasts.
- FTC impaired myoblast differentiation as shown by microscopy.
- TAF and FTC increased senescence markers in human stem cells.
Takeaway
This study looks at how a specific receptor in the body might help us understand why some people with HIV have weak muscles when they take certain medications.
Methodology
The effects of anti-retroviral therapies FTC and TAF were tested in mouse myoblast cell lines and human stem cells.
Limitations
Further research is needed to fully understand the mechanisms involved.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website